GlassScriptPhysician profile
Jeffrey W Krenzer
NPI 1962455899
$5,214.64
in general payments reported to CMS, 2019-2025
51 companies · $90.00 in 2025
The $90.00 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,011 · 2020: $1,634 · 2021: $2,072 · 2022: $310 · 2023: $53.52 · 2024: $44.85 · 2025: $90.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $188.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $433.09 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $418.22 | 2019-2021 | |
| Abbvie INC. | $408.70 | 2019-2022 | |
| Glaxosmithkline, LLC. | $345.56 | 2019-2022 | |
| Novo Nordisk INC | $308.34 | 2019-2021 | |
| Amgen INC. | $299.96 | 2019-2021 | |
| Lilly USA, LLC | $260.13 | 2019-2022 | |
| Eisai INC. | $203.74 | 2020-2021 | |
| Allergan, INC. | $181.63 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $177.55 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $172.65 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $139.20 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $127.78 | 2019-2021 | |
| Optinose US, INC. | $123.48 | 2019-2021 | |
| Abbott Laboratories | $120.39 | 2022-2023 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Krenzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.